The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current number of shares outstanding is 1,769,181,294. At the end of 2022 the company had 1,769,181,294 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2022 | 1.76 B | 0.05% |
2021 | 1.76 B | 0.18% |
2020 | 1.76 B | 19.35% |
2019 | 1.47 B | 0.01% |
2018 | 1.47 B | -7.12% |
2017 | 1.59 B | -0.02% |
2016 | 1.59 B | -1.08% |
2015 | 1.60 B | 1.16% |
2014 | 1.59 B | 0.25% |
2013 | 1.58 B | 0.47% |
2012 | 1.58 B | -2.23% |
2011 | 1.61 B |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 5,607,000,000 | 216.93% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 950,182,000 | -46.29% | ๐บ๐ธ USA |
![]() Amgen AMGN | 535,000,000 | -69.76% | ๐บ๐ธ USA |
![]() Biogen BIIB | 144,100,000 | -91.85% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 1,255,000,000 | -29.06% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 2,133,000,000 | 20.56% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 3,096,000,000 | 75.00% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | 2,017,000,000 | 14.01% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | 95,800,000 | -94.59% | ๐บ๐ธ USA |